Literature DB >> 25990306

Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.

Rik Ossenkoppele1, Niklas Mattsson2, Charlotte E Teunissen3, Frederik Barkhof4, Yolande Pijnenburg5, Philip Scheltens5, Wiesje M van der Flier6, Gil D Rabinovici7.   

Abstract

Different clinical variants of probable Alzheimer's disease (AD) share underlying plaques and tangles but show distinct atrophy patterns. We included 52 posterior cortical atrophy, 29 logopenic variant primary progressive aphasia, 53 early-onset and 42 late-onset AD patients, selected for abnormal cerebrospinal fluid (CSF)-amyloid-beta42, with CSF and magnetic resonance imaging data available. Bootstrapping revealed no differences in the prevalence of abnormal CSF total-tau and phosphorylated-tau between probable AD variants (range total-tau: 84.9%-92.3%, phosphorylated-tau: 79.2%-93.1%, p > 0.05). Voxelwise linear regressions showed various relationships between lower CSF-Aβ42 and syndrome-specific atrophy, involving precuneus, posterior cingulate, and medial temporal lobe in early-onset AD, occipital cortex and middle temporal gyrus in posterior cortical atrophy; anterior cingulate, insular cortex and precentral gyrus (left > right) in logopenic variant primary progressive aphasia; and medial temporal lobe, thalamus, and temporal pole in late-onset AD (all at p < 0.001 uncorrected). In contrast, CSF-tau was not related to gray matter atrophy in any group. Our findings suggest that lower CSF-amyloid-beta42 - and not increased total-tau and phosphorylated-tau - relates to reduced gray matter volumes, mostly in regions that are typically atrophied in distinct clinical variants of probable AD.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Amyloid; Atrophy; Cerebrospinal fluid; Magnetic resonance imaging; Tau

Mesh:

Substances:

Year:  2015        PMID: 25990306      PMCID: PMC4465267          DOI: 10.1016/j.neurobiolaging.2015.04.011

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  74 in total

1.  Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Authors:  Nicolas Villain; Gaël Chételat; Blandine Grassiot; Pierrick Bourgeat; Gareth Jones; Kathryn A Ellis; David Ames; Ralph N Martins; Francis Eustache; Olivier Salvado; Colin L Masters; Christopher C Rowe; Victor L Villemagne
Journal:  Brain       Date:  2012-05-23       Impact factor: 13.501

2.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

3.  Early onset Alzheimer's disease is associated with a distinct neuropsychological profile.

Authors:  Lieke L Smits; Yolande A L Pijnenburg; Esther L G E Koedam; Annelies E van der Vlies; Ilona E W Reuling; Teddy Koene; Charlotte E Teunissen; Philip Scheltens; Wiesje M van der Flier
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

4.  CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy.

Authors:  Thomas P Baumann; Hüseyin Duyar; Marc Sollberger; Jens Kuhle; Axel Regeniter; Baltazar Gomez-Mancilla; Klaus Schmidtke; Andreas U Monsch
Journal:  Dement Geriatr Cogn Disord       Date:  2010-07-01       Impact factor: 2.959

5.  The topography of grey matter involvement in early and late onset Alzheimer's disease.

Authors:  Giovanni B Frisoni; Michela Pievani; Cristina Testa; Francesca Sabattoli; Lorena Bresciani; Matteo Bonetti; Alberto Beltramello; Kiralee M Hayashi; Arthur W Toga; Paul M Thompson
Journal:  Brain       Date:  2007-02-09       Impact factor: 13.501

6.  CSF biomarkers in posterior cortical atrophy.

Authors:  J Seguin; M Formaglio; A Perret-Liaudet; I Quadrio; Y Tholance; O Rouaud; C Thomas-Anterion; B Croisile; H Mollion; O Moreaud; M Salzmann; A Dorey; M Bataillard; M-H Coste; A Vighetto; P Krolak-Salmon
Journal:  Neurology       Date:  2011-04-27       Impact factor: 9.910

7.  Variability in cognitive presentation of Alzheimer's disease.

Authors:  Cheryl L Stopford; Julie S Snowden; Jennifer C Thompson; David Neary
Journal:  Cortex       Date:  2007-11-17       Impact factor: 4.027

8.  Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease.

Authors:  Christiane Möller; Hugo Vrenken; Lize Jiskoot; Adriaan Versteeg; Frederik Barkhof; Philip Scheltens; Wiesje M van der Flier
Journal:  Neurobiol Aging       Date:  2013-04-03       Impact factor: 4.673

9.  CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.

Authors:  A E van der Vlies; N A Verwey; F H Bouwman; M A Blankenstein; M Klein; P Scheltens; W M van der Flier
Journal:  Neurology       Date:  2009-03-24       Impact factor: 9.910

10.  Patterns of longitudinal brain atrophy in the logopenic variant of primary progressive aphasia.

Authors:  Jonathan D Rohrer; Francesca Caso; Colin Mahoney; Maya Henry; Howard J Rosen; Gil Rabinovici; Martin N Rossor; Bruce Miller; Jason D Warren; Nick C Fox; Gerard R Ridgway; Maria Luisa Gorno-Tempini
Journal:  Brain Lang       Date:  2013-02-08       Impact factor: 2.381

View more
  20 in total

1.  Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts.

Authors:  Nienke M E Scheltens; Betty M Tijms; Teddy Koene; Frederik Barkhof; Charlotte E Teunissen; Steffen Wolfsgruber; Michael Wagner; Johannes Kornhuber; Oliver Peters; Brendan I Cohn-Sheehy; Gil D Rabinovici; Bruce L Miller; Joel H Kramer; Philip Scheltens; Wiesje M van der Flier
Journal:  Alzheimers Dement       Date:  2017-04-17       Impact factor: 21.566

2.  The association between tau PET and retrospective cortical thinning in clinically normal elderly.

Authors:  Molly R LaPoint; Jasmeer P Chhatwal; Jorge Sepulcre; Keith A Johnson; Reisa A Sperling; Aaron P Schultz
Journal:  Neuroimage       Date:  2017-05-22       Impact factor: 6.556

Review 3.  Early-Onset Alzheimer Disease.

Authors:  Mario F Mendez
Journal:  Neurol Clin       Date:  2017-05       Impact factor: 3.806

4.  Alzheimer's disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation.

Authors:  Cathrine Petersen; Amber L Nolan; Elisa de Paula França Resende; Zachary Miller; Alexander J Ehrenberg; Maria Luisa Gorno-Tempini; Howard J Rosen; Joel H Kramer; Salvatore Spina; Gil D Rabinovici; Bruce L Miller; William W Seeley; Helmut Heinsen; Lea Tenenholz Grinberg
Journal:  Acta Neuropathol       Date:  2019-06-27       Impact factor: 17.088

5.  A Systematic Review of MicroRNA Expression as Biomarker of Late-Onset Alzheimer's Disease.

Authors:  Soraya Herrera-Espejo; Borja Santos-Zorrozua; Paula Álvarez-González; Elixabet Lopez-Lopez; África Garcia-Orad
Journal:  Mol Neurobiol       Date:  2019-06-25       Impact factor: 5.590

Review 6.  Early-onset Alzheimer Disease and Its Variants.

Authors:  Mario F Mendez
Journal:  Continuum (Minneap Minn)       Date:  2019-02

7.  Visual Ratings of Medial Temporal Lobe Atrophy Correlate with CSF Tau Indices in Clinical Variants of Early-Onset Alzheimer Disease.

Authors:  Elias Granadillo; Pongsatorn Paholpak; Mario F Mendez; Edmond Teng
Journal:  Dement Geriatr Cogn Disord       Date:  2017-07-05       Impact factor: 2.959

8.  The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials.

Authors:  Jeffrey Cummings
Journal:  Alzheimers Dement       Date:  2018-06-21       Impact factor: 21.566

Review 9.  New insights into atypical Alzheimer's disease in the era of biomarkers.

Authors:  Jonathan Graff-Radford; Keir X X Yong; Liana G Apostolova; Femke H Bouwman; Maria Carrillo; Bradford C Dickerson; Gil D Rabinovici; Jonathan M Schott; David T Jones; Melissa E Murray
Journal:  Lancet Neurol       Date:  2021-03       Impact factor: 44.182

10.  Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jennifer M Nicholas; Ulf Andreasson; Nadia K Magdalinou; Kaj Blennow; Jason D Warren; Cath J Mummery; Martin N Rossor; Michael P Lunn; Sebastian J Crutch; Nick C Fox; Henrik Zetterberg; Jonathan M Schott
Journal:  J Neurol       Date:  2015-09-26       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.